Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKIP: Doxycycline for Panitumumab-Induced Skin Toxicity in mCRC
NCT01418742Phase 2Terminated
- Sponsor
- GMIHO Gesellschaft für Medizinische Innovation - Hämatologie und Onkologie
- Start
- Aug 2011
- Primary completion
- May 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in drug-induced skin toxicity comparing Doxycycline Arm with Placebo Arm (2 arms). Primary endpoint: Time until unblinding of skin therapy allocation due to insufficient efficacy at 30 months. Started Aug 2011; status: terminated.
02
Drugs
doxycycline
03
Conditions
drug-induced skin toxicity
Beyond the preview
Go deeper on NCT01418742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01418742.